Purpose

The purpose of this study is to determine the safety and efficacy of nab-paclitaxel and gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic cancer.

Category

IRB Number
20150799HU
NCT Number
-
Open to Enrollment
Yes
Sponsor
Eli Lilly and Company -



Study Contact

Regulatory Point of Contact
Andrea Hansis-Diarte
210-567-3208
hansisdiarte@uthscsa.edu



Eligibility

Eligible Ages
18 Years -
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

    Exclusion Criteria